First GIS Analysis of Modern Stone Tools Used by Wild Chimpanzees (Pan troglodytes verus) in Bossou, Guinea, West Africa Por Benito-Calvo, A, Carvalho, S, Arroyo, A, Matsuzawa, T, de la Torre, I

Wild monkeys flake stone tools. Por Proffitt, T, Luncz, L, Falótico, T, Ottoni, E, de la Torre, I, Haslam, M

Neutralizing monoclonal antibodies for treatment of COVID-19 Por Taylor, PC, Adams, AC, Hufford, MM, De La Torre, I, Winthrop, K, Gottlieb, RL

Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis Por Keystone, EC, Genovese, MC, Schlichting, DE, de la Torre, I, Beattie, SD, Rooney, TP, Taylor, PC

Tool skill impacts the archaeological evidence across technological primates Por Luncz, LV, Slania, NE, Almeida-Warren, K, Carvalho, S, Falótico, T, Malaivijitnond, S, Arroyo, A, de la Torre, I, Proffitt, T

Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis – going beyond treat-to-target Por Taylor, P, Van de Laar, M, Laster, A, Fakhouri, W, Quebe, A, de la Torre, I, Jain, S

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis Por Fautrel, B, Alten, R, Kirkham, B, de la Torre, I, Durand, F, Barry, J, Holzkaemper, T, Fakhouri, W, Taylor, P

Association between baseline haemoglobin levels and radiographic joint damage progression in patients with rheumatoid arthritis treated with baricitinib or standard of care Por Moeller, B, Durez, P, Finckh, A, Lopez-Romero, P, Perrier, C, de Leonardis, F, De La Torre, I, Taylor, P

Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications Por Taylor, PC, Bieber, T, Alten, R, Witte, T, Galloway, J, Deberdt, W, Issa, M, Haladyj, E, De La Torre, I, Grond, S, Wollenberg, A

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience Por Taylor, PC, Laedermann, C, Alten, R, Feist, E, Choy, E, Haladyj, E, De La Torre, I, Richette, P, Finckh, A, Tanaka, Y

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM Por Fautrel, B, Kirkham, B, Pope, J, Takeuchi, T, Gaich, C, Quebe, A, Zhu, B, De La Torre, I, De Leonardis, F, Taylor, P

Non-linear thermal resistance model for the simulation of high power GaN-based devices Por Garciá-Sánchez, S., Iñiguez-de-la-Torre, I., Pérez, S., Ranjan, Kumud, Agrawal, Manvi, Lingaparthi, R., Dharmarasu, Nethaji, Radhakrishnan, K., Arulkumaran, Subramaniam, Ng, Geok Ing, González, T., Mateos, J.

Obter o texto integral

On the practical limitations for the generation of Gunn oscillations in highly doped GaN diodes Por Garcia-Sanchez, S., Daher, M. Abou, Lesecq, M., Huo, Lili, Lingaparthi, R., Dharmarasu, Nethaji, Radhakrishnan, K., Iniguez-De-La-Torre, I., Vasallo, B. G., Perez, S., Gonzalez, T., Mateos, J.

Obter o texto integral

Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patient... Por Fautrel, B, Zhu, B, Taylor, P, van de Laar, M, Emery, P, De Leonardis, F, Gaich, C, Nicolay, C, Kadziola, Z, De La Torre, I, Fleischmann, R

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patient... Por Fautrel, B, Zhu, B, Taylor, PC, van de Laar, M, Emery, P, De Leonardis, F, Kannowski, CL, Nicolay, C, Kadziola, Z, De La Torre, I, Fleischmann, R

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis Por Emery, P, Dudler, J, Smolen, J, Zerbini, C, Burmester, G, Fautrel, B, Van Der Laar, M, Fleischmann, R, Fakhouri, W, De Leonardis, F, Zhu, B, Kadziola, Z, De La Torre, I, Perrier, C, Taylor, P

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summar... Por Taylor, P, Krogulec, M, Dudek, A, Dudler, J, Drescher, E, Cseuz, R, Kausiene, R, Andersone, D, Unikiene, D, Sanchez Burson, J, Blanco Alonso, R, Dvorak, Z, Ghizdavescu, A, Irto, I, Larsson, E, Bello, N, Barry, J, Durand, F, Holzkaemper, T, Otawa, S, De Bono, S, Keystone, E, Rubbert-Roth, A, Combe, B, De La Torre, I